EU/3/15/1516: Orphan designation for the treatment of pancreatic cancer
Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL
Table of contents
Overview
On 28 July 2015, orphan designation (EU/3/15/1516) was granted by the European Commission to Lokon Pharma AB, Sweden, for modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL for the treatment of pancreatic cancer.
The sponsor’s address was updated in June 2020.
Key facts
Active substance |
Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL
|
Intended use |
Treatment of pancreatic cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/15/1516
|
Date of designation |
28/07/2015
|
Sponsor |
Lokon Pharma AB |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: